Showing results (21-30 of 37) with videos related to
Sort By:
Pageof 4
Journal of Medical Virology|October 22, 2020
Extrapulmonary manifestations of severe acute respiratory syndrome coronavirus-2 infectionHugo R Rosen, Casey O'Connell, Mitra K Nadim, et al.Epigenetics|September 24, 2010
A phase I biological study of azacitidine (Vidaza™) to determine the optimal dose to inhibit DNA methylationIlan Bernstein, Hyang-Min Byun, Ann Mohrbacher, et al.Human Pathology|October 6, 2014
Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literatureMaria E Vergara-Lluri, Caroline I Piatek, Vinod Pullarkat, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|September 5, 2006
The occurrence of vaginal infections among HIV-infected and high-risk HIV-uninfected women: longitudinal findings of the women's interagency HIV studyD Heather Watts, Gayle Springer, Howard Minkoff, et al.European Journal of Haematology|July 15, 2026
Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY-1 and MOMENTUM TrialsFrancesca Palandri, Casey O'Connell, Pankit Vachhani, et al.Hepatology (Baltimore, Md.)|May 19, 2018
Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular CarcinomaMinmin Liu, Lian Zhang, Hongtao Li, et al.Leukemia Research|June 3, 2021
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional databaseDouglas Tremblay, Lukas Ronner, Nikolai Podoltsev, et al.Leukemia Research|June 19, 2022
Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center databaseNoa Rippel, Douglas Tremblay, Nicole Zubizarreta, et al.Cancer Letters|September 10, 2022
DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinomaLian Zhang, Hong-Tao Li, Rachel Shereda, et al.Haematologica|March 16, 2012
Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patientsKrisstina Gowin, Prakash Thapaliya, Jan Samuelson, et al.Pageof 4